Julie Faltum is a forward-thinking biopharmaceutical executive who is excited about progressing science, improving outcomes for patients and delivering value to the healthcare ecosystem. Julie’s global and U.S. experience comes from small, midsized and big pharma such as Lundbeck, Novo Nordisk, Sanofi and Mallinckrodt as well as management consulting e.g., for biotech and startups.
She has extensive experience and track record in across all stages of drug development especially pipeline asset management, commercial development of new products, market access and business development, the last ten years at the V.P. level, across multiple therapy areas including hemostasis, diabetes, acute and chronic orphan and rare diseases.
While at Novo Nordisk Julie was part of the Hemostasis Business Unit involved in the rFVIIa (NovoSeven) indication expansion program and other hemostatic agents. Notably, she co-led the global Ph. 3 trauma development program and Ph. 2 cardiac surgery program and played a pivotal role in the external engagement with global thought leaders (civilian and military) as well as scientific societies.
Julie also has extensive commercial leadership as well as pricing, market access and HEOR leadership experience that includes three global launches for example second-to-market GLP-1 Victoza for Type 2 Diabetes, which became a blockbuster within two years, and she has worked on multiple assets over her 20+ year biopharma career.
Finally, Julie has her own consulting business, she is a Senior Advisor at HealthTech180, an advisory and consulting healthcare platform focusing on technology transfer and venture building in Europe.
Julie Faltum is a Danish national residing in the U.S., and she studied and worked in multiple countries including Denmark, Italy, Switzerland and the U.S. She holds a MSc in International Business from Copenhagen Business School, a CEMS Master (CBS & Bocconi) and a post graduate degree in Pharmaceutical Medicine (ECPM) from University of Basel.